Purdue Pharma Says Trial Timing Won't Sway Bankruptcy Call
- Company said to be considering protection as liability looms
- Oklahoma AG says drugmakers know they can’t win over a jury
Bottles of Purdue Pharma L.P. OxyContin medication sit on a pharmacy shelf in Provo, Utah.
Photographer: George Frey/Bloomberg
This article is for subscribers only.
Purdue Pharma LLP says its decision on whether to file for bankruptcy to avoid being swamped by opioid lawsuits doesn’t depend on the timing of the first trial over its role in the public-health crisis.
A judge in Oklahoma Friday refused Purdue’s, Johnson & Johnson’s and Teva Pharmaceutical Industries Ltd.’s requests to push back a May trial of Oklahoma officials’ suit seeking to recover as much as $25 billion in current and future costs of dealing with the opioid epidemic